New White Paper - Read AAM Report on Drug Shortages
  • AAM 2023 Generic and Biosimilar Medicines Savings in the U.S. Report
    NEW: 2023 U.S. Generic & Biosimilar Medicines Savings Report
    Savings continue to grow with $408 billion saved in 2022 for the U.S. health care system, including patients, employers and taxpayers. Representing 90% of Rx filled but less than 18% of spending, generics and biosimilars are an integral part of the U.S. health care system.
  • AAM White Paper on Shortages
    Drug shortages, which hit crisis proportions between 2010 and 2011, can be a challenge for manufacturers, providers, and patients. Due to aggressive efforts by industry and the Food and Drug Administration (FDA), the incidence of shortages has declined, but recent reports suggest a rise in shortages in 2023.
  • FDA Commissioner Dr. Robert Califf
    FDA Commissioner Dr. Robert Califf at GRx+Biosims 2023
    We’re thrilled to announce that Dr. Robert Califf will be our keynote FDA speaker, joining us in-person for a special “Fireside Chat.” Don’t miss this opportunity to hear from top industry professionals and thought leaders!
    What Do You Take #4GRxANTED?
    The generic and biosimilar industry is working with Direct Relief to donate doses of medicines across the U.S. to people in need. You can be part of this collective effort by recording a short video on what you take for granted and sharing on social media with #4GRxANTED and @4GRxANTED.
  • Semglee Launch Tracking 2023
    PBMs Are Blocking Patient Access to Biosimilar Insulin
    A new report from AAM’s Biosimilars Council shows that even as patient demand for biosimilar insulin has grown dramatically, PBMs are continuing to restrict patient access and drive up drug prices.
  • Fireside chat with Mark Cuban at Access! 2023
    "You guys make such a huge difference that you don't get credit for."
    Mark Cuban on generic medicines.
  • GRx+Biosims 2023
    Join Us at GRx+Biosims 2023
    GRx+Biosims 2023 is the premier scientific & regulatory and policy event for the U.S. generics and biosimilars industry, featuring timely programming relevant to technical, regulatory and policy professionals. Top officials and subject-matter experts share their knowledge and best practices to enhance attendees' understanding of how to succeed in generic and biosimilar development, regulatory process and approvals, and the evolving policy landscape.
  • Study Finds Middlemen Increasingly Block Patient Access to New Generics
    New report shows that middlemen like health plans and pharmacy benefit managers (PBMs) increasingly block patient access, delaying coverage of new generics in favor of higher-priced brand drugs with high rebates.
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

Our Brands and Campaigns

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.